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Edited by Veli-Pekka LehtoAbstract The small proteoglycan decorin plays an important
role in the organisation of the extracellular matrix by binding to
several components, including collagen and ﬁbronectin. In this
work, we report the dose-dependent and saturable interaction of
decorin with the adhesive glycoprotein, von Willebrand factor
(VWF). This interaction was mediated by the glycosaminoglycan
side chain of decorin and was critically regulated by the degree of
sulfation, but not by the amount of iduronic acid. Both
chondroitin sulfate and dermatan sulfate, in addition to heparin,
were found to bind VWF equally well. Although soluble decorin
prevented VWF binding to heparin, puriﬁed VWF-A1 domain
failed to interact with the proteoglycan. These results identify
VWF as a new partner for the small proteoglycan, decorin, in the
structural organisation of the extracellular matrix.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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von Willebrand factor (VWF) is a multimeric adhesive
protein, which plays a crucial role in platelet adhesion to the
subendothelial matrix. At the site of vessel wall injury, binding
of VWF to the GPIb-IX-V receptor on circulating platelets
promotes cell rolling and tethering, eventually leading to ﬁrm
platelet adhesion and thrombus formation [1,2]. The mature
VWF molecule contains four repeated A, B, C, and D domains
[3]. The A1 domain contains the platelet-binding site, and in-
teracts with the leucine-rich repeats (LRRs) and ﬂanking se-
quences in the GPIba subunit of the GPIb-IX-V complex [4,5].
Subendothelial VWF interacts with diﬀerent components of
the extracellular matrix, including collagen and the glycos-
aminoglycan (GAG), heparin [6,7]. VWF binds to heparin
through the A1 domain and through a sequence in the N-
terminus of the protein [7,8]. Some studies have suggested that
this interaction may inﬂuence platelet adhesion [9,10]. VWF
interaction with collagen is mediated by both the A1 and A3* Corresponding author. Fax: +39-382-507240.
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doi:10.1016/j.febslet.2004.08.011domains [11]. Recent ﬁndings have suggested that incorpora-
tion of VWF into ﬁbrillar collagen enhances platelet adhesion
[12].
Decorin is a member of the small leucine-rich proteoglycan
family comprising a 40 kDa protein core with 10 LRRs bound
to a single chondroitin/dermatan sulfate (CS/DS) side chain
[13]. Decorin from diﬀerent tissues shows great heterogeneity
in terms of both CS/DS ratio and degree of sulfation of the
GAG chain [14]. Decorin regulates matrix assembly by binding
to several proteins including thrombospondin, ﬁbronectin and
collagen. In particular, decorin binding to collagen negatively
modulates the lateral association of collagen molecules, re-
sulting in a reduction of ﬁbril diameter [15]. Decorin also in-
teracts with growth factors and growth factors receptors to
regulate cellular responses [16,17]. We have previously shown
that decorin also supports both platelet adhesion and activa-
tion by binding to the integrin a2b1 [18].
In this work, we report that decorin directly binds VWF.
This interaction is supported by the CS/DS side chain of the
proteoglycan and does not involve the A1 domain of VWF.
These results identify decorin as a new physiological partner
for VWF, and provide evidence for a more complex interplay
among collagen, VWF, and decorin in the organisation of the
subendothelial matrix.2. Materials and methods
2.1. Materials
Heparin, CS, DS, chondro-4-sulfatase, chondro-6-sulfatase, o-
phenylenediamine dihydrochloride (OPD) tablets, and anti-collagen
type I antibody were from Sigma (Milan, Italy). Chondroitinase ABC
and ACII were from Seikagaku (Tokyo, Japan). Puriﬁed human VWF
and isolated VWF A1 domain were prepared as described [19,20].
Microtiter plates were from Nunc International (Roskilde, Denmark).
Collagen type I was purchased from Collagen Corporation (Freemont,
CA, USA). Anti-VWF antibody, C20, was from Santa Cruz Biotech-
nology (Heidelberg, Germany). Peroxidase-conjugated anti-VWF an-
tibody was from Dako (Lostrup, Denmark). The anti-A1 domain
monoclonal antibodies have been previously characterised [21]. Per-
oxidase-conjugated secondary antibodies were obtained from Bio-Rad
(Milan, Italy). Chemiluminescence reaction reagents were from Pierce.2.2. Decorin puriﬁcation and characterisation
Decorin was puriﬁed from bovine tendon or aorta by extraction with
4 M guanidine hydrochloride, ultracentrifugation on a CsCl gradient,
and ion-exchange chromatography essentially as previously described
[22,23]. Each decorin preparation was characterised by SDS–PAGE,
N-terminal sequencing, and circular dichroism spectroscopy, as
described [18,24]. Moreover, the presence of possible contaminatingation of European Biochemical Societies.
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immunochemical detection. No hydroxyproline was detected and the
amount of proline evaluated by amino acid analysis was consistent
with that expected for puriﬁed decorin. No traces of collagen were
detected using speciﬁc antibodies (data not shown).
2.3. Solid phase binding assay
Wells of microtiter plates were coated in triplicate with 4 lg of BSA,
collagen, decorin, or decorin protein core (in 50 ll of PBS), or with 8
lg of heparin, puriﬁed decorin GAG chain, CS, or DS (in 50 ll of
NaHCO3 buﬀer, pH 9.6) for 16 h at 4 C. The eﬃciency of coating with
GAGs was veriﬁed by uronic acid assay on the adsorbed materials and
found to be comparable for all the GAGs used in this study (data not
shown). Upon coating, wells were washed four times with 500 ll of
washing buﬀer (0.15 M NaCl, 0.05% Tween 20) and incubated with
100 ll of 1% BSA in PBS for 1 h at room temperature. After three
washes, plates were incubated with 2 lg of puriﬁed VWF in 50 ll of
PBS (unless otherwise stated) for 2 h at room temperature. Bound
VWF was detected by incubation of the wells with peroxidase-conju-
gated anti-VWF antibody (1:5000 dilution in PBS containing 1% BSA
and 0.05% Tween 20) for 2 h at room temperature. After three washes,
the colorimetric reaction was initiated by addition of 50 ll of substrate
solution (0.04% OPD, 0.04% H2O2, 514 mM Na2HPO4, and 24.3 mM
citric acid, pH 5), and stopped, after 10 min, with 50 ll of 3 N HCl.
Absorbance was measured at 490 nm using an ELISA microplate
reader. In some experiments, the puriﬁed A1 domain (0.5 lg in 50 ll of
PBS) instead of intact VWF was added to decorin, heparin, or colla-
gen-coated wells. In these cases, bound protein was detected using a
mixture of three diﬀerent monoclonal antibodies against the A1 do-
main (6G2, CRI, and 5D2, 0.5 lg in PBS containing 1% BSA and
0.05% Tween 20) followed by a peroxidase-conjugated secondary anti-Fig. 1. Binding of VWF to decorin. (A) Polystyrene plates were coated with
and then incubated with (+) or without ()) 2 lg of puriﬁed VWF for 2 h. Boun
a peroxidase-conjugated anti-VWF antibody. Results are means S.D. of
rin from aorta were spotted onto nitrocellulose and incubated with puriﬁe
after incubation with an antibody against VWF and a peroxidase-conjugat
experiments.mouse antibody (1:5000 in PBS containing 1% BSA and 0.05% Tween
20). The colorimetric reaction was performed using OPD substrate, as
described above.
2.4. Overlay experiments
Ten lg of decorin puriﬁed from aorta or tendon, BSA, or collagen
were spotted onto nitrocellulose membranes using a Bio-Dot micro-
ﬁltration apparatus (Bio-Rad). Membranes were blocked with 5% BSA
in TBS for 1 h at room temperature and then incubated with puriﬁed
VWF (40 lg/ml solution in PBS) for 16 h at 4 C. Nitrocellulose
membranes were then washed 4 times with 10 ml of washing buﬀer
(0.05 mM Tris, 0.2 NaCl, 0.1 % polyethylene glycol 20 000, 0.1% BSA,
and 0.05% Tween 20, pH 7.4) and then incubated with anti-VWF
antibodies (1:200 dilution in washing buﬀer) for 2 h at room temper-
ature. Upon extensive washing, membranes were incubated with per-
oxidase-conjugated secondary antibody and reactive protein visualised
by enhanced chemiluminescence reaction.
2.5. Enzymatic digestions of decorin and analysis of disaccharide
composition
Enzymatic digestions of decorin were performed to prepare the de-
corin protein core and to allow further characterisation of the GAG
chains by HPLC analysis. Decorin was digested with chondroitinase
ABC, chondroitinase ACII, chondro-4-sulfatase, chondro-6-sulfatase,
or papain essentially as described [25,26]. After digestion with ABCase
and ACII, the resultant disaccharides were analysed by HPLC using a
Supelcosil column (TM-SAX 1, Supelco) equilibrated with 5 mM
KH2PO4, pH 4.5. Elution was performed using a linear gradient (from
5 to 400 mMKH2PO4) at a ﬂow rate of 1 ml/min, with detection at 232
nm. The percentage content of iduronic acid in the samples was cal-
culated as described [27].BSA, collagen, heparin, decorin from tendon and decorin from aorta,
d protein was revealed by a colorimetric reaction upon incubation with
three diﬀerent experiments. (B) BSA, decorin from tendon and deco-
d VWF. Bound protein was revealed by a chemiluminescent reaction
ed anti-mouse antibody. The ﬁgure is representative of three diﬀerent
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A potential interaction between VWF and decorin was in-
vestigated by a solid-phase binding assay using immobilised
ligands and soluble puriﬁed VWF. Fig. 1A shows that puriﬁed
VWF failed to bind immobilised albumin, but interacted with
both heparin and collagen, as expected. Moreover, VWF was
found to also bind decorin puriﬁed from both tendon and
aorta. The interaction between VWF and decorin was con-
ﬁrmed by dot-blot assay. Fig. 1B shows that decorin, puriﬁed
from either tendon or aorta and spotted onto nitrocellulose,
supported binding of VWF with similar eﬃciency. In the light
of these results, subsequent experiments were performed with
decorin obtained from tendon, a much richer and easier to
obtain source of the proteoglycan.
A time course of VWF binding to immobilised decorin is
reported in Fig. 2A. The amount of bound protein increased
progressively and reached the maximum after 2 h of incuba-
tion. The speciﬁcity of VWF binding to decorin was then in-
vestigated by incubating increasing amounts of puriﬁed VWF
with immobilised decorin or BSA. Fig. 2B shows that VWFFig. 2. Kinetics and saturation binding of VWF to decorin. (A) Immobilize
increasing times, and the amount of bound protein was revealed by incub
meansS.D. of three diﬀerent experiments. (B) Immobilised decorin (black s
of puriﬁed VWF for 2 h, and bound protein revealed using a peroxidase-con
are means S.D. of three diﬀerent experiments. The inset shows a Scatchard-
value was calculated per VWF subunit, assuming a molecular mass of 275 kbinding to decorin was dose-dependent and saturable. A
modiﬁed Scatchard-type analysis was performed according to
a previously described approach [7,24,28,29] and revealed a
single binding site for VWF, with an apparent Kd of about
20 nM.
Binding of VWF to decorin was drastically reduced by in-
creasing the ionic strength, but was not aﬀected by high con-
centrations of Triton X-100, suggesting an ionic rather than
hydrophobic interaction (Fig. 3). In order to identify the re-
gion of decorin involved in VWF binding, solid-phase binding
assays were performed with isolated protein core or GAG
chain, obtained upon decorin digestion with chondroitinase
ABC, or papain, respectively. Fig. 4 shows that decorin GAG
chain was able to bind VWF in a very similar manner to the
intact proteoglycan. By contrast, VWF only minimally inter-
acted with the isolated decorin protein core. These results in-
dicate that binding of VWF to decorin occurs mainly through
interaction with the CS/DS chain.
The composition of the GAG side chain of decorin iso-
lated from diﬀerent tissues is rather variable in terms of di-
saccharide composition and sulfation level [14]. Therefore, ind decorin from tendon was incubated with 2 lg of puriﬁed VWF for
ation with a peroxidase-conjugated anti-VWF antibody. Results are
quares) or BSA (open squares) was incubated with increasing amounts
jugated anti-VWF antibody followed by a colorimetric reaction. Data
type plot of the experimental data for VWF binding to decorin. The Kd
Da.
Fig. 3. Eﬀect of increased ionic strength on VWF binding to decorin. Immobilized decorin was incubated with 2 lg of puriﬁed WVF in the presence
of increased concentrations of NaCl, or 1% Triton X-100, as indicated. Bound protein was revealed upon incubation a peroxidase-conjugated anti-
VWF antibody. Results are meansS.D. of three diﬀerent experiments.
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for VWF binding, we analysed the composition of the GAG
chains of the decorin preparations from tendon and aorta.
The results are summarised in Table 1. The GAG chain of
decorin from tendon was primarily composed of CS, con-
taining about 80% glucuronic acid-galactosamine disaccha-
ride. By contrast, decorin from aorta was mainly composed
of DS, as it contained about 80% iduronic acid-galactos-
amine. In both cases, however, the degree of sulfation of the
GAG chain was very similar and greater than 90%. Fig. 4
clearly shows that removal of sulfate groups from the GAG
chain completely abolished the binding of VWF to decorin.
A comparable inhibition of VWF binding was observed
upon digestion of decorin with either chondro-4-sulfatase, or
chondro-6-sulfatase, or with the two enzymes added together
(Fig. 4), suggesting that both 4- and 6-sulfates are important
for protein interaction. Analysis of decorin GAG chain re-
vealed that non-sulfated disaccharides increased from 8.86%Fig. 4. VWF binding to GAGs. Wells of microtiter plates were coated with
decorin obtained by digestion with chondro-4-sulfatase and chondro-6- sulfa
des. decorin, respectively), chondroitin sulfate (CS), dermatan sulfate (DS) o
measured as described above. Results are means S.D. of three diﬀerent exto 78.25% upon treatment with chondro-4- and 6-sulfatases,
conﬁrming the eﬃciency of the digestion. Moreover, we
found that, in addition to heparin, CS and DS were also
able to bind VWF with similar eﬃciency (Fig. 4). As re-
ported in Table 1, the CS used in these studies did not
contain any detectable iduronic acid, while glucuronic acid in
DS was about 2% of the total level of uronic acid. These
results indicate that the diﬀerent ratio of CS/DS in the GAG
chain of decorin does not drastically aﬀect VWF binding, as
long as the negative charges of the sulfate groups are
maintained.
We next investigated whether interaction with decorin
could aﬀect the ability of VWF to bind immobilised heparin.
Fig. 5A shows that soluble decorin inhibited, in a dose-de-
pendent manner, the interaction of VWF not only with im-
mobilised decorin, but also with heparin. These results
suggest that decorin and heparin may share common binding
sites on the VWF molecule. Since a major heparin bindingBSA, decorin, decorin GAG chain, decorin protein core, desulfated
tase, alone and in combination (4-des. decorin, 6-des. decorin, and 4-6-
r heparin, as indicated. VWF binding to immobilised ligands was then
periments.
Table 1
Analysis of GAGs composition
GlcUA (%) IduUA (%) SO24 /100 res
Decorin tendon 78.8 21.2 92.63
Decorin aorta 21.6 78.4 91.18
CS 100 0 96.59
DS 2.15 97.85 91.82
The GAG chains of decorin from tendon and from aorta, as well as
commercially available CS and DS, were characterised in terms of
percentage of glucuronic acid (GlcUA) and iduronic acid (IduUA),
and sulfate content, as described in Section 2.
Fig. 5. Analysis of the decorin binding domain on VWF. (A) Puriﬁed
VWF (2 lg) was incubated with immobilised decorin (black squares)
or heparin (open squares) in the presence of increasing amounts of
soluble decorin. Bound VWF was then revealed by reaction with a
peroxidase-conjugated anti-VWF antibody. Results are expressed as %
of speciﬁc binding, calculated upon subtraction of the binding to BSA
coated wells. The binding of VWF in the absence of added soluble
decorin has been considered as 100%. Results are means S.D. of
three diﬀerent experiments. When not evident, standard deviations are
within the open or black squares. (B) Puriﬁed VWF (black bars) or
isolated VWF A1 domain (dotted bars) was incubated with immobi-
lised BSA, decorin, heparin and collagen for 2 h. The binding to the
immobilised molecules was revealed by immunoreaction with anti-
VWF antibody or with a mixture of three diﬀerent monoclonal anti-
bodies against VWF A1. Results are means S.D. of three diﬀerent
experiments.
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certained whether this domain was involved in the interac-
tion with decorin. Fig. 5B shows that in contrast to intact
VWF, the isolated A1 domain was unable to bind immobi-
lised decorin, but eﬃciently recognised both heparin and
collagen, as expected. Moreover, we found that three dif-
ferent monoclonal antibodies against the A1 domain did not
alter the interaction of VWF with decorin (data not shown).Therefore, these results argue against a role for the VWF A1
domain in decorin binding.4. Discussion
In this work, we have identiﬁed the small proteoglycan de-
corin as a new interactor of VWF. Direct binding between
decorin and VWF was demonstrated by both solid phase and
overlay assays, and found to be speciﬁc, dose-dependent, sat-
urable, and mainly mediated by the GAG chain of the pro-
teoglycan. Although the decorin protein core contains 10
LRRs similar to those present in the GPIba subunit of the
platelet receptor for VWF, it does not seem to play a major
role in VWF binding. On the other hand, the ﬁnding that the
decorin GAG chain fully supports interaction with VWF is in
line with the reported ability of VWF to interact with heparin
[7,8]. This interaction, whose biological signiﬁcance is largely
unclear, has been generally considered a circumstantial evi-
dence for the ability of VWF to interact with proteoglycans
containing sulfated disaccharides, although this has never been
experimentally conﬁrmed. Therefore, our results represent the
ﬁrst direct evidence for the ability of VWF to bind oligosac-
charide chains diﬀerent from heparin and physiologically
present in proteoglycans of the extracellular matrix. The GAG
chain of decorin is a mixture of CS and DS, whose relative
abundance is greatly diﬀerent, depending on the tissue type
and age of the molecule [14]. In particular, we found that the
iduronic acid content of decorin from bovine tendon was only
about 20% of the total uronic acid content, but reached almost
80% in decorin from aorta. Despite this, both decorin prepa-
rations were equally able to bind VWF. Recently, decorin has
been shown to also bind tenascin-X through the GAG chain,
but this interaction has been found to be mediated by DS, but
not CS, stretches [30]. Therefore, although the content of
iduronic acid has been generally considered critical for the
ability of GAG chains to display biological eﬀects, our results
indicate that this parameter is not signiﬁcantly relevant for the
ability of the GAG chain of decorin to bind VWF. This is also
supported by the ﬁnding that puriﬁed CS chains, which did not
contain iduronic acid, interacted with VWF with the same
eﬃciency as DS chains containing almost exclusively iduronic
acid. By contrast, we found that the degree of sulfation of
galactosamine residues is critical for VWF binding. In fact,
enzymatic removal of the sulfate groups completely abolished
the ability of decorin to bind VWF. Therefore, interaction
between decorin and VWF in diﬀerent tissues may be modu-
lated by the degree of decorin sulfation, rather than by a dif-
ferent degree of glucuronic acid conversion into iduronic acid.
Although decorin prevented VWF binding to heparin, our
results with antibodies against the A1 domain, as well as with
isolated A1 domain, which represents, together with a region
in the N-terminus of the protein, a known heparin binding
region, excluded a direct involvement of this domain in decorin
binding. This ﬁnding may have physiological consequences.
The A1 domain mediates many biological activities of VWF,
including its interaction with collagen and platelets [4,6].
Therefore, it is likely that interaction with decorin does not
directly compete with the ability of VWF to bind collagen or
to stimulate platelets. Moreover, it is known that decorin binds
to collagen through the protein core and is incorporated into
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can associate with multimeric VWF in the subendothelium,
through direct binding to the A1 and A3 domains [11]. The
results presented in this work indicate that an additional direct
interaction may occur within this macromolecular complex
between VWF and the GAG chain of decorin. Therefore, our
results are indicative of a more complex organisation of the
extracellular matrix, and suggest that a trimeric complex in-
cluding collagen ﬁbres, decorin and VWF is the real molecular
entity of the subendothelial matrix that is presented to circu-
lating platelets at the site of vessel wall injury. It is noteworthy
that all three proteins can bind and activate platelets. More-
over, in contrast to the interaction with VWF, decorin binding
to platelets involves the protein core rather than the GAG
chain [18]. Whether interaction between decorin and VWF and
their incorporation into collagen ﬁbrils may result in an ad-
ditive or synergistic eﬀect on platelet activation is currently
under investigation.
In conclusion, our results report a new direct interaction
between two important elements of the extracellular matrix,
the multimeric adhesive protein VWF and the small proteo-
glycan decorin. This ﬁnding provides new insights in the
complexity of the architecture of the subendothelial matrix,
and may have relevant physiological implications for the
ability of these components to stimulate platelet adhesion and
activation at the site of vascular injury.
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